Opendata, web and dolomites

ImmUniverse SIGNED

Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImmUniverse project word cloud

Explore the words cloud of the ImmUniverse project. It provides you a very rough idea of what is the project "ImmUniverse" about.

prospective    enormous    tackle    combine    predictive    countries    formed    assays    biomarker    microenvironment    omics    disruptive    compare    datasets    therapies    understand    recirculating    burden    monitor    corresponding    regard    biomarkers    implementing    worldwide    hence    tailor    mechanistic    liquid    methodology    ulcerative    heterogeneity    observational    precision    imid    patient    severity    diagnostics    systematically    improvement    reduce    employing    treatment    interactions    prerequisites    immune    limitations    individual    validated    realization    tissue    circulating    atopic    medicine    diagnosis    technologies    diseases    disease    significantly    socioeconomic    combination    immuniverse    detectable    unmet    crosstalk    cells    signature    inform    biopsies    progression    profiling    clinical    dermatitis    respective    adequately    medical    imids    biopsy    time    transdisciplinary    therapy    outcome    monitoring    colitis    signatures    course    industrialized    mediated    fill    anticipated    cohorts    invasive    gap    cross   

Project "ImmUniverse" data sheet

The following table provides information about the project.

Coordinator
HUMANITAS UNIVERSITY 

Organization address
address: VIA RITA LEVI MONTALCINI SNC
city: PIEVE EMANUELE
postcode: 20090
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 31˙110˙000 €
 EC max contribution 15˙500˙000 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-15-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS UNIVERSITY IT (PIEVE EMANUELE) coordinator 1˙970˙093.00
2    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL DE (KIEL) participant 2˙613˙900.00
3    AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH AT (WIEN) participant 2˙133˙236.00
4    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 1˙248˙421.00
5    JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH AT (GRAZ) participant 834˙408.00
6    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 740˙000.00
7    UNIVERSITE DU LUXEMBOURG LU (ESCH-SUR-ALZETTE) participant 687˙000.00
8    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 659˙793.00
9    VIB VZW BE (ZWIJNAARDE - GENT) participant 652˙500.00
10    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 626˙062.00
11    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 564˙047.00
12    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 504˙988.00
13    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 492˙475.00
14    INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA LU (Esch-sur-Alzette) participant 402˙501.00
15    SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO S ANNA IT (PISA) participant 362˙000.00
16    AARHUS UNIVERSITETSHOSPITAL DK (AARHUS) participant 355˙596.00
17    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY FR (NANCY CEDEX) participant 340˙783.00
18    AARHUS UNIVERSITET DK (AARHUS C) participant 199˙847.00
19    EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS BE (BRUXELLES) participant 50˙312.00
20    EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING BE (Brussels) participant 50˙250.00
21    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) participant 11˙781.00
22    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
23    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
24    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
25    PFIZER LIMITED UK (SANDWICH) participant 0.00
26    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00

Map

 Project objective

Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNIVERSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNIVERSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

TRIC-TB (2019)

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Read More  

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More